流感疫苗接种能否减轻突破性感染的严重程度?叙述性综述与进一步研究建议
该叙述性综述检索了社区成人及≥6月龄儿童实验室确诊流感后,比较接种与未接种者病情严重程度的文献,共纳入38篇。对满足合并条件的指标进行荟萃分析发现,接种与成人流感住院患者ICU入住几率降低26%、死亡风险降低31%相关,儿童发热几率降低45%相关,但肺炎临床诊断和成人门诊后住院风险无显著关联。结果支持流感疫苗接种可能减轻突破性感染的疾病进程。
要点
- 成人流感住院患者中,接种者ICU入住几率降低26%(OR=0.74,95%CI 0.58,0.93)。
- 成人流感住院患者中,接种者死亡风险降低31%(OR=0.69,95%CI 0.52,0.92)。
- 儿童流感病毒感染中,接种与发热几率降低45%相关(OR=0.55,95%CI 0.42,0.71)。
核心结论
- 流感疫苗接种可能减轻突破性流感病毒感染的疾病严重程度。
研究设计与样本
- 叙述性综述,纳入38篇已发表文章,报告实验室确诊流感者接种状态与21项严重程度指标中至少1项的关联。
- 研究对象为社区居住的成人及≥6月龄儿童,当同一结局和年龄类别至少有4个同类型效应估计时进行荟萃分析。
主要发现
- 成人流感住院患者中,接种与ICU入住几率降低26%相关(OR=0.74,95%CI 0.58,0.93;8项研究)。
- 成人流感住院患者中,接种与死亡风险降低31%相关(OR=0.69,95%CI 0.52,0.92;5项研究)。
- 儿童流感病毒感染中,接种与发热几率降低45%相关(OR=0.55,95%CI 0.42,0.71;4项研究)。
- 成人流感住院患者中,接种与肺炎临床诊断无显著关联(OR=0.92,95%CI 0.82,1.04)。
- 成人门诊流感后住院风险与接种无显著关联(OR=0.60,95%CI 0.28,1.28)。
关键数值与推荐
- 仅5项严重程度指标满足计算合并效应的标准。
- 研究方法和效应估计高度异质。
临床怎么用
- 可为推荐流感疫苗接种以减轻突破性感染后重症风险提供证据支持。
- 接种后仍可能感染流感,但成人住院者ICU入住和死亡风险、儿童发热几率可能更低。
局限性
- 叙述性综述,研究方法和效应估计高度异质。
- 仅5项严重程度指标满足合并标准,多数指标无法汇总。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The effect of influenza vaccination on influenza severity remains uncertain. We reviewed the literature for evidence to inform the question of whether influenza illness is less severe among individuals who received influenza vaccination compared with individuals with influenza illness who were unvaccinated prior to their illnesses. We conducted a narrative review to identify published findings comparing severity of influenza outcomes by vaccination status among community-dwelling adults and children ≥ 6 months of age with laboratory-confirmed influenza illness. When at least four effect estimates of the same type (e.g., odds ratio) were available for a specific outcome and age category (children versus adults), data were pooled with meta-analysis to generate a summary effect estimate. We identified 38 published articles reporting ≥ 1 association between influenza vaccination status and one of 21 indicators of severity of influenza illness among individuals with laboratory-confirmed influenza. Study methodologies and effect estimates were highly heterogenous, with only five severity indicators meeting criteria for calculating a combined effect. Among eight studies, influenza vaccination was associated with 26% reduction in odds of ICU admission among adults with influenza-associated hospitalization (OR = 0.74, 95% CI 0.58, 0.93). Among five studies of adults with influenza-associated hospitalization, vaccinated patients had 31% reduced risk of death compared with unvaccinated patients (OR = 0.69, 95% CI 0.52, 0.92). Among four studies of children with influenza virus infection, vaccination was associated with an estimated 45% reduction in the odds of manifesting fever (OR = 0.55, 95% CI 0.42, 0.71). Vaccination was not significantly associated with receiving a clinical diagnosis of pneumonia among adults hospitalized with influenza (OR = 0.92, 95% CI 0.82, 1.04) or with risk of hospitalization following outpatient influenza illness among adults (OR = 0.60, 95% CI 0.28, 1.28). Overall, our findings support the hypothesis that influenza vaccination may attenuate the course of disease among individuals with breakthrough influenza virus infection.
引用
- Ferdinands JM, Thompson MG, Blanton L, et al. Does influenza vaccination attenuate the severity of breakthrough infections? A narrative review and recommendations for further research. Vaccine. 2021. PMID: 34090700. doi:10.1016/j.vaccine.2021.05.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。